BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Pulmonx (LUNG)PulmonxCompany update

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx granted equity awards under its 2025

Related news

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

DCTHDelcath Systems2026-09-11 20:01 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INSMInsmed2026-09-04 11:00 EST

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PLSEPulse Biosciences2026-09-04 11:00 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STIMNeuronetics2026-07-31 21:00 EST

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RXSTRxSight2026-07-26 20:00 EST

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

INSMInsmed2026-09-21 11:00 EST

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Stock data

Close
1.78 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States